[Preclinical study of the safety of the antihistaminic preparation dimebon].
The antihistaminic drug dimebon was subjected to toxicological study. It was demonstrated that as regards the level of the mean lethal doses dimebon can be attributed to little toxic substances. Administration of the drug in the doses approximating the therapeutic ones (1 and 5 mg/kg) for 2 months did not produce any alterations in rats, guinea-pigs or dogs. When administered in high doses (10 and 70 mg/kg) the drug provoked compensated abnormalities of some functions of the liver and kidneys in the presence of moderate and reversible structural changes in these organs. Dimebon did not exert any local irritating effect on the gastrointestinal tract. Administration of the drug in doses of 150 and 300 mg/kg at different times of pregnancy (days 1-7, 8-13, 14-19) did not produce any embryolethal or teratogenic effects.
Golubeva
M I
MI
Shashkina
L F
LF
Proĭnova
V A
VA
Fedorova
E A
EA
Nechushkina
L V
LV
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology; D000818:Animals; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian / Q000187:drug effects; D005260:Female; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000633:toxicity*; D007211:Indoles / Q000633:toxicity*; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D051381:Rats; D013997:Time Factors
D006634:Histamine H1 Antagonists; D007211:Indoles; C010119:latrepirdine
Doklinicheskoe izuchenie bezvrednosti antigistaminnogo preparata dimebona.